热休克蛋白90在乳腺癌发生发展及治疗中的研究进展  

Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer

作　　者：宗禹萱(综述) 庞达(审校)[1] ZONG Yuxuan;PANG Da(The 1st Ward of Mammary Gland,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院乳腺一病区,哈尔滨150081

出　　处：《实用肿瘤学杂志》2022年第4期381-385,共5页Practical Oncology Journal

摘　　要：乳腺癌已成为发病率最高的恶性肿瘤之一。热休克蛋白90(HSP90)被称为分子伴侣,其在合成多肽、控制蛋白数量、蛋白折叠、调控蛋白活性和蛋白降解过程中发挥重要作用。HSP90可调节细胞生长、粘附、侵袭、转移、血管生成和细胞凋亡等,在乳腺癌发展过程中起重要的作用。HSP90抑制剂在抵抗肿瘤生长和抑制侵袭方面发挥积极作用,成为一种新的治疗手段。本文就HSP90与乳腺癌的关系,以及HSP90抑制剂介导的乳腺癌治疗新模式进行阐述。Breast cancer has become one of the malignant tumors highest incidence.Heat shock protein 90(HSP90)is called a molecular chaperone,which plays an important role in the synthesis of peptide,control of protein quantity,protein folding,activity and degradation.HSP90 can regulate cell growth,adhesion,invasion,metastasis,angiogenesis and apoptosis,etc,and plays an important role in the development of breast cancer.HSP90 inhibitors play an active role in resisting tumor growth and inhibiting invasion,becoming a new treatment method.This article further elucidates the relationship between HSP90 and breast cancer,and the new mode of breast cancer treatment mediated by HSP90 inhibitors.

关 键 词：乳腺癌 热休克蛋白90 热休克蛋白90抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]